Enanta Pharmaceuticals Inc (ENTA)

[willyw]

Enanta Pharmaceuticals Announces AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease

http://ir.enanta.com/phoenix.zhtml?c=147990&p=irol-newsArticle&ID=2222520


98 percent of patients across all major HCV genotypes (GT1-6) with severe chronic kidney disease (CKD), including patients on dialysis, achieved SVR12 with 12 weeks of G/P in the primary intent-to-treat analysis, regardless of previous treatment status or presence of compensated cirrhosis
100 percent of patients achieved SVR12 in a modified intent-to-treat analysis
G/P is an investigational, pan-genotypic, once-daily, ribavirin-free, fixed-dose combination for the treatment of chronic HCV
G/P includes Enanta’s second protease inhibitor glecaprevir (ABT-493)